Guardant Health (GH) Stock Price, News & Analysis

Company Overview

Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company that develops blood-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients over time. Its liquid biopsy technologies analyze tumor-related signals in blood, reducing the need for tissue biopsies in certain clinical and research settings.

The company’s products include Guardant360 tests, which profile advanced cancers and can help identify potentially actionable genomic alterations; Guardant Reveal, which is used to assess residual disease and recurrence risk; and Guardant Shield, a blood-based screening test for colorectal cancer. Guardant also provides testing and data services to biopharmaceutical companies developing cancer treatments and conducting clinical research.

Founded in 2012 and headquartered in Palo Alto, California, Guardant Health serves healthcare providers, patients, biopharmaceutical companies and researchers. Its commercial and research activities primarily focus on the United States, with its tests and services also supporting international oncology and drug-development markets.

Key Stats

• Today's Range: $156.28 to $161.40
• 50-Day Range: $143.62 to $170.92
• 52-Week Range: $53.40 to $176.58
• Volume: 695,456 shs
• Average Volume: 1.90 million shs
• Market Capitalization: $21.12 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $188.13
• Consensus Rating: Moderate Buy

Guardant Health Stock Analysis - MarketRank™

Guardant Health scored higher than 66% of companies evaluated by MarketBeat, and ranked 322nd out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Guardant Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.96, and is based on 1 strong buy rating, 24 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Guardant Health has a consensus price target of $188.13, representing about 19.5% upside from its current price of $157.38.

Amount of Analyst Coverage

Guardant Health has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Guardant Health are expected to grow in the coming year, from ($2.98) to ($2.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Guardant Health is -45.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Guardant Health is -45.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.72% of the float of Guardant Health has been sold short.

Short Interest Ratio / Days to Cover

Guardant Health has a short interest ratio ("days to cover") of 5.25.

Change versus previous month

Short interest in Guardant Health has recently decreased by 1.26%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Guardant Health does not currently pay a dividend.

Dividend Growth

Guardant Health does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.81

News Sentiment

Guardant Health has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Guardant Health this week, compared to 9 articles on an average week.

Search Interest

19 people have searched for GH on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.

MarketBeat Follows

13 people have added Guardant Health to their MarketBeat watchlist in the last 30 days. This is an increase of 117% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Guardant Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $67,113,285.00 in company stock.

Percentage Held by Insiders

5.60% of the stock of Guardant Health is held by insiders.

Percentage Held by Institutions

92.60% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 9/12/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/15/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:GH
• CIK: 1576280
• Web: www.guardanthealth.com
• Phone: (855) 698-8887
• Fax: 888-974-4258
• Employees: 2,506
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Guardant Health: $188.13
• High Price Target: $225.00
• Low Price Target: $120.00
• Potential Upside/Downside: +19.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.96
• Research Coverage: 26 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$416.28 million
• Net Margins: -38.33%
• Pretax Margin: -38.41%
• Return on Equity: N/A
• Return on Assets: -25.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.03
• Quick Ratio: 3.71

Sales & Book Value

• Annual Sales: $1.18 billion
• Price / Sales: 17.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.79) per share
• Price / Book: -199.22

Miscellaneous

• Outstanding Shares: 134,196,000
• Free Float: 126,681,000
• Market Cap: $21.12 billion
• Optionable: Not Optionable
• Beta: 1.57